Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (9994)	1/13/2004 7:49:37 AM
From: the hube	Read Replies (1) \| Respond to of 52153

Myriad Genetics' Cancer Drug Candidate MPI-176716 Causes Ovarian Tumor Remission biz.yahoo.com Tuesday January 13, 6:30 am ET SALT LAKE CITY, Jan. 13 /PRNewswire-FirstCall/ -- Myriad Genetics, Inc. (Nasdaq: MYGN - News), today announced progress with its anti-cancer compound, MPI-176716. The drug candidate is in the final stages of preclinical development prior to submission to the FDA as an Investigational New Drug (IND). The new data released by the Company demonstrates the drug's exceptional potency in killing cancer cells and its ability to cause tumor regression in animal models of ovarian cancer. MPI-176716 was tested against OVCAR tumor cells in a mouse xenograft model. Myriad's drug candidate was evaluated in comparison to the current standard of care in ovarian cancer therapy, carboplatin. MPI-176716 was given to the mice in combination with carboplatin, using saline as control. Compared with saline control, carboplatin alone reduced tumor volume by approximately 20%, a significant achievement against this notoriously difficult tumor. But remarkably, when MPI-176716 was combined with carboplatin, the tumors were sent into remission, regressing essentially 100% by the end of the trial. At the end of the 55 day study period, the MPI-176716 treated mice had an ending tumor volume that was below measurement range. "We are excited by the potential of this promising drug candidate to treat a variety of cancer types," said Peter Meldrum, President and Chief Executive Officer of Myriad Genetics, Inc. "There are few options available to treat aggressive tumors such as ovarian cancer and we are not aware of any drug on the market that shows as great a level of activity against the OVCAR ovarian cancer tumor model. We intend to vigorously move this drug candidate into human clinical trials this year." Myriad discovered the drug's anti-cancer target through the use of its proprietary genetics and protein interaction technologies. MPI-176716, a small molecule drug candidate, was discovered using Myriad's proprietary library of approximately 300,000 proprietary molecules, followed by a medicinal chemistry program. Myriad has formulated a preferred IV (intravenous) preparation of the drug candidate in preparation for human clinical trials. MPI-176716 induces apoptosis in cancer cell lines. The drug candidate has demonstrated a good early safety profile. It has broad anti-cancer activity as established against a variety of solid tumors and blood cancers in culture. MPI-176716 was tested in parallel with cisplatin and etoposide, two common anti-neoplastic compounds used to treat certain ovarian cancer, bladder cancer, lung cancer, testicular cancer and non-hodgkins lymphoma cases. MPI-176716 was more potent than either, killing cancer cells rapidly. It was 30 times more potent than Cisplatin and 20 times more potent than Etoposide. Cancer is uncontrolled growth and spread of abnormal cells. Normal cells go through a programmed process of cell death called apoptosis, part of the body's constant effort to rejuvenate itself. Cancer cells have managed to avoid this process, and become immortal. MPI-176716 selectively induces apoptosis in cancer cells, causing them, in essence, to self-destruct. Myriad Genetics, Inc. is a leading biopharmaceutical company focused on the development of novel healthcare products. The Company develops and markets proprietary predictive medicine and personalized medicine products, and is developing and intends to market a number of promising therapeutic products that address large potential markets. Myriad's news and other information are available on the Company's Web site at www.myriad.com .